How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
9
VVOS Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
-37.89%
Day range:
$1.66 - $1.80
52-week range:
$1.66 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.85x
P/B ratio:
6.07x
Volume:
128.5K
Avg. volume:
138.4K
1-year change:
-58.5%
Market cap:
$15.4M
Revenue:
$15M
EPS (TTM):
-$1.97
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VVOS
Vivos Therapeutics, Inc.
|
$7.1M | -$0.48 | 91.91% | -0.69% | $5.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$18M | -- | 11.04% | -- | $36.00 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VVOS
Vivos Therapeutics, Inc.
|
$1.71 | $5.00 | $15.4M | -- | $0.00 | 0% | 0.85x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.5600 | $12.3077 | $190.3M | -- | $0.00 | 0% | 173.58x |
|
ELMD
Electromed, Inc.
|
$29.09 | $36.00 | $242.6M | 31.30x | $0.00 | 0% | 3.88x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.11 | $14.20 | $164.9M | 31.01x | $0.00 | 0% | 1.22x |
|
VNRX
VolitionRX Ltd.
|
$0.26 | $2.20 | $31.9M | -- | $0.00 | 0% | 17.82x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.64 | $1.50 | $88.9M | 62.25x | $0.00 | 0% | 0.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VVOS
Vivos Therapeutics, Inc.
|
83.15% | 1.547 | 48.77% | 0.77x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.105 | -- | 4.58x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VVOS
Vivos Therapeutics, Inc.
|
$3.6M | -$4.7M | -153.33% | -315.1% | -69.79% | -$4.1M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Vivos Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VVOS or CATX?
Perspective Therapeutics, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of -12425.36%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About VVOS or CATX?
Vivos Therapeutics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 192.4%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 380.77%. Given that Perspective Therapeutics, Inc. has higher upside potential than Vivos Therapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Vivos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VVOSVivos Therapeutics, Inc.2 1 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is VVOS or CATX More Risky?
Vivos Therapeutics, Inc. has a beta of 6.895, which suggesting that the stock is 589.464% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock VVOS or CATX?
Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VVOS or CATX?
Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Vivos Therapeutics, Inc.'s net income of -$5.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 0.85x versus 173.58x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M CATXPerspective Therapeutics, Inc.173.58x -- $209K -$26M
-
Which has Higher Returns VVOS or ELMD?
Electromed, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of 12.65%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About VVOS or ELMD?
Vivos Therapeutics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 192.4%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 23.75%. Given that Vivos Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VVOSVivos Therapeutics, Inc.2 1 0 ELMDElectromed, Inc.4 0 0 -
Is VVOS or ELMD More Risky?
Vivos Therapeutics, Inc. has a beta of 6.895, which suggesting that the stock is 589.464% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.
-
Which is a Better Dividend Stock VVOS or ELMD?
Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VVOS or ELMD?
Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Vivos Therapeutics, Inc.'s net income of -$5.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 0.85x versus 3.88x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M ELMDElectromed, Inc.3.88x 31.30x $16.9M $2.1M
-
Which has Higher Returns VVOS or INFU?
InfuSystem Holdings, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of 6.19%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About VVOS or INFU?
Vivos Therapeutics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 192.4%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 75.09%. Given that Vivos Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VVOSVivos Therapeutics, Inc.2 1 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is VVOS or INFU More Risky?
Vivos Therapeutics, Inc. has a beta of 6.895, which suggesting that the stock is 589.464% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock VVOS or INFU?
Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VVOS or INFU?
Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Vivos Therapeutics, Inc.'s net income of -$5.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 0.85x versus 1.22x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M INFUInfuSystem Holdings, Inc.1.22x 31.01x $36.5M $2.3M
-
Which has Higher Returns VVOS or VNRX?
VolitionRX Ltd. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of -862.39%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About VVOS or VNRX?
Vivos Therapeutics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 192.4%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 746.15%. Given that VolitionRX Ltd. has higher upside potential than Vivos Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Vivos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VVOSVivos Therapeutics, Inc.2 1 0 VNRXVolitionRX Ltd.4 2 0 -
Is VVOS or VNRX More Risky?
Vivos Therapeutics, Inc. has a beta of 6.895, which suggesting that the stock is 589.464% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock VVOS or VNRX?
Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VVOS or VNRX?
Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Vivos Therapeutics, Inc.'s net income of -$5.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 0.85x versus 17.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M VNRXVolitionRX Ltd.17.82x -- $627.3K -$5.4M
-
Which has Higher Returns VVOS or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of 3.93%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About VVOS or XTNT?
Vivos Therapeutics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 192.4%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 136.22%. Given that Vivos Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VVOSVivos Therapeutics, Inc.2 1 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is VVOS or XTNT More Risky?
Vivos Therapeutics, Inc. has a beta of 6.895, which suggesting that the stock is 589.464% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock VVOS or XTNT?
Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VVOS or XTNT?
Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Vivos Therapeutics, Inc.'s net income of -$5.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 62.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 0.85x versus 0.69x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VVOSVivos Therapeutics, Inc.0.85x -- $6.8M -$5.4M XTNTXtant Medical Holdings, Inc.0.69x 62.25x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
